Neurology Central

Anti-NMDAR antibodies as a new piece in schizophrenia’s puzzle

Schizophrenia is a chronic psychiatric disorder marked by psychotic symptoms (i.e., hallucinations and delusions), behavioral changes (e.g., apathy, social withdrawal) and cognitive dysfunction (e.g., executive impairment) [1]. Affecting roughly 1% of the general population, schizophrenia exerts a significant socioeconomic burden due to its severity.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.